What did we learn from new oral anticoagulant treatment?

被引：5

作者：

Esmon, Charles T. ^{[1
,2
,3
]}

机构：

[1] Oklahoma Med Res Fdn, Howard Hughes Med Inst, Coagulat Biol Lab, Oklahoma City, OK 73104 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA

[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA

来源：

THROMBOSIS RESEARCH | 2012年 / 130卷

关键词：

Direct thrombin inhibitor; Direct factor Xa inhibitor; Stroke; Heart attack; Deep vein thrombosis; Atrial fibrillation; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; FACTOR-XA; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; WARFARIN; FONDAPARINUX; ARTHROPLASTY; PREVENTION;

D O I：

10.1016/j.thromres.2012.08.271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Orally active direct inhibitors of thrombin and factor Xa have now been approved for treatment or prevention of deep vein thrombosis, and stroke associated with atrial fibrillation. The factor Xa inhibitor, rivaroxaban, has shown promising results in the treatment of acute coronary syndromebut is not yet approved for that indication. These agents share a rapid onset and are clearedwith half lives of approximately 10 hours. At present there is no approved antidote for either class of anticoagulant, making the treatment of life-threatening bleeding episodes problematic. These agents have fewer drug interactions than warfarin, have a predictable clearance, and hence do not requiremonitoring. Patientswith renal insufficiency have delayed clearance and hence may have elevated levels of the drug leading to increased risk of bleeding. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：S41 / S43

页数：3

共 19 条

[1] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].